Is FULC or MCRB more profitable?

Fulcrum Therapeutics' return on equity of -27.80% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -27.80% -26.32% Seres Therapeutics N/A -130.29% -35.35%

Is IKT or MCRB more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Seres Therapeutics N/A -130.29% -35.35%

Seres Therapeutics (MCRB) Competitors

$7.74 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$7.86 +0.12 (+1.55%)

As of 07/2/2026 05:31 PM Eastern

Compare

MCRB vs. NAGE, IVVD, ACIU, FULC, and IKT

Should you buy Seres Therapeutics stock or one of its competitors? MarketBeat compares Seres Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Seres Therapeutics include Niagen Bioscience (NAGE), Invivyd (IVVD), AC Immune (ACIU), Fulcrum Therapeutics (FULC), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.

How does Seres Therapeutics compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Niagen Bioscience has a net margin of 14.29% compared to Seres Therapeutics' net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
Seres Therapeutics	N/A	-130.29%	-35.35%

Niagen Bioscience has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$130.42M	2.09	$17.38M	$0.21	16.33
Seres Therapeutics	$1.15M	65.35	$5.70M	-$5.17	N/A

In the previous week, Niagen Bioscience's average media sentiment score of 0.00 equaled Seres Therapeutics'average media sentiment score.

Company	Overall Sentiment
Niagen Bioscience	Neutral
Seres Therapeutics	Neutral

Niagen Bioscience currently has a consensus price target of $10.50, indicating a potential upside of 206.12%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 119.64%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, equities analysts clearly believe Niagen Bioscience is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Niagen Bioscience has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Summary

Niagen Bioscience beats Seres Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Seres Therapeutics compare to Invivyd?

Seres Therapeutics (NASDAQ:MCRB) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Seres Therapeutics has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$1.15M	65.35	$5.70M	-$5.17	N/A
Invivyd	$53.43M	4.93	-$52.49M	-$0.31	N/A

Seres Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Invivyd	-138.90%	-53.48%	-41.56%

Seres Therapeutics has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Seres Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 119.64%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 795.05%. Given Invivyd's stronger consensus rating and higher probable upside, analysts plainly believe Invivyd is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Invivyd had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Invivyd and 0 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.00 equaled Invivyd'saverage media sentiment score.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Invivyd	Neutral

Summary

Invivyd beats Seres Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to AC Immune?

AC Immune (NASDAQ:ACIU) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Seres Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Seres Therapeutics	N/A	-130.29%	-35.35%

Seres Therapeutics has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$3.70M	69.00	-$85.03M	-$0.82	N/A
Seres Therapeutics	$1.15M	65.35	$5.70M	-$5.17	N/A

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, AC Immune had 5 more articles in the media than Seres Therapeutics. MarketBeat recorded 5 mentions for AC Immune and 0 mentions for Seres Therapeutics. AC Immune's average media sentiment score of 0.79 beat Seres Therapeutics' score of 0.00 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Positive
Seres Therapeutics	Neutral

AC Immune has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

AC Immune presently has a consensus target price of $7.50, suggesting a potential upside of 198.80%. Seres Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 119.64%. Given AC Immune's stronger consensus rating and higher possible upside, equities research analysts plainly believe AC Immune is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

AC Immune beats Seres Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Fulcrum Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 113.54%. Seres Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 119.64%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Fulcrum Therapeutics had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 0 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.00 beat Fulcrum Therapeutics' score of -0.08 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Fulcrum Therapeutics	Neutral
Seres Therapeutics	Neutral

Fulcrum Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Seres Therapeutics has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.20	-$74.88M	-$1.15	N/A
Seres Therapeutics	$1.15M	65.35	$5.70M	-$5.17	N/A

Fulcrum Therapeutics' return on equity of -27.80% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Seres Therapeutics	N/A	-130.29%	-35.35%

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Fulcrum Therapeutics beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Inhibikase Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Inhibikase Therapeutics currently has a consensus price target of $5.40, indicating a potential upside of 171.36%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 119.64%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 0 mentions for Seres Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.30 beat Seres Therapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Seres Therapeutics	Neutral

Seres Therapeutics has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,010.54	-$48.26M	-$0.43	N/A
Seres Therapeutics	$1.15M	65.35	$5.70M	-$5.17	N/A

Inhibikase Therapeutics' return on equity of -41.31% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Seres Therapeutics	N/A	-130.29%	-35.35%

Summary

Inhibikase Therapeutics beats Seres Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MCRB vs. The Competition

Export

Metric	Seres Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$74.95M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.50	21.61	28.02	24.70
Price / Sales	65.35	340.22	540.55	99.42
Price / Cash	7.12	147.12	49.26	57.09
Price / Book	1.58	8.66	10.96	6.46
Net Income	$5.70M	$23.81M	$3.57B	$337.01M
7 Day Performance	9.32%	3.39%	2.12%	1.69%
1 Month Performance	16.74%	10.81%	5.25%	3.81%
1 Year Performance	-31.84%	62.61%	33.29%	23.90%

Seres Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MCRB Seres Therapeutics	3.5469 of 5 stars	$7.74 flat	$17.00 +119.6%	-31.8%	$74.95M	$1.15M	N/A	330	Gap Up
NAGE Niagen Bioscience	3.7879 of 5 stars	$3.30 -3.5%	$10.50 +218.2%	-73.0%	$272.38M	$129.42M	15.71	120	Analyst Forecast Gap Down
IVVD Invivyd	2.3319 of 5 stars	$0.94 +5.8%	$8.00 +747.7%	+18.7%	$262.70M	$53.43M	N/A	100	Gap Down
ACIU AC Immune	3.1899 of 5 stars	$2.66 +3.9%	$7.50 +182.0%	+21.8%	$260.54M	$4.31M	N/A	140	News Coverage Positive News Analyst Forecast
FULC Fulcrum Therapeutics	3.8964 of 5 stars	$3.73 -1.8%	$8.20 +119.8%	-45.2%	$253.21M	$80M	N/A	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Competitors

MCRB vs. NAGE, IVVD, ACIU, FULC, and IKT

How does Seres Therapeutics compare to Niagen Bioscience?

Summary

How does Seres Therapeutics compare to Invivyd?

Summary

How does Seres Therapeutics compare to AC Immune?

Summary

How does Seres Therapeutics compare to Fulcrum Therapeutics?

Summary

How does Seres Therapeutics compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seres Therapeutics (MCRB) Competitors

MCRB vs. NAGE, IVVD, ACIU, FULC, and IKT

How does Seres Therapeutics compare to Niagen Bioscience?

Do insiders & institutionals believe in NAGE or MCRB?

Is NAGE or MCRB more profitable?

Which has higher valuation & earnings, NAGE or MCRB?

Does the media prefer NAGE or MCRB?

Do analysts rate NAGE or MCRB?

Which has more volatility & risk, NAGE or MCRB?

Summary

How does Seres Therapeutics compare to Invivyd?

Do insiders and institutionals hold more shares of MCRB or IVVD?

Which has stronger valuation & earnings, MCRB or IVVD?

Is MCRB or IVVD more profitable?

Which has more volatility and risk, MCRB or IVVD?

Do analysts rate MCRB or IVVD?

Does the media prefer MCRB or IVVD?

Summary

How does Seres Therapeutics compare to AC Immune?

Is ACIU or MCRB more profitable?

Which has stronger valuation and earnings, ACIU or MCRB?

Do insiders & institutionals hold more shares of ACIU or MCRB?

Does the media prefer ACIU or MCRB?

Which has more volatility and risk, ACIU or MCRB?

Do analysts prefer ACIU or MCRB?

Summary

How does Seres Therapeutics compare to Fulcrum Therapeutics?

Do analysts prefer FULC or MCRB?

Does the media favor FULC or MCRB?

Which has more volatility & risk, FULC or MCRB?

Which has stronger earnings & valuation, FULC or MCRB?

Is FULC or MCRB more profitable?

Do insiders and institutionals have more ownership in FULC or MCRB?

Summary

How does Seres Therapeutics compare to Inhibikase Therapeutics?

Do insiders & institutionals have more ownership in IKT or MCRB?

Which has more volatility & risk, IKT or MCRB?

Do analysts prefer IKT or MCRB?

Does the media refer more to IKT or MCRB?

Which has better earnings & valuation, IKT or MCRB?

Is IKT or MCRB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools